With a profitable model, two acquisitions already completed and a platform deployed across more than 500 healthcare facilities, Sêmeia is not a startup in search of validation. It is a player that has proven its model and is now raising funds to accelerate its growth.
This 21 million euro fundraising illustrates the growing maturity of a market that is structuring itself around a handful of dominant players.
Analysis by the experts at Auris Finance, advisors in mergers, acquisitions and financial engineering.
Sêmeia has announced a 21 million euro fundraising from Acton Capital, XAnge via Mutuelles Impact and Citizen Capital. Existing investors, including Banque des Territoires and Orange Ventures, are also taking part in the deal.
The arrival of Acton Capital, a high-conviction German fund, alongside existing investors who are doubling down, conveys a simple message: the model is validated, the trajectory is clear. Sêmeia generates between 6 and 7 million euros in annual revenue, a level of traction rarely seen for a French healthtech at this stage of development, which fully justifies the calibre of the investors gathered around the table.
A fundraising driven by a consolidator’s momentum
Founded in 2017 in Toulouse by Pierre Hornus, Daniel Szeftel and Mathieu Godart, Sêmeia has established itself as the benchmark player in remote medical monitoring with its MedicWise platform, a CE-marked class IIa medical device deployed in more than 500 healthcare facilities and used to monitor 35,000 patients.
This position is not the result of organic growth alone. Sêmeia has already acquired Optim’Care in 2022 and Healabs in 2025, clearly positioning itself as the benchmark consolidator in the remote medical monitoring solutions market. The Optim’Care acquisition gave it control of more than 80% of the market share for remote monitoring of chronic kidney disease and transplantation. The 21 million euros raised are in line with this same logic: targeted acquisitions and additional partnerships with digital health players are envisaged to enrich the user experience and further integrate the solution into existing care pathways.
Therapeutic expansion as a driver of valuation
What underpins Sêmeia’s competitive position is the depth of its clinical coverage. The MedicWise platform, particularly thanks to past acquisitions, covers five therapeutic areas: nephrology, organ transplantation, mental health, cardiology and lung transplantation. In nephrology, its historical market, Sêmeia reports a 26% reduction in hospitalisations and a 73% reduction in medical time spent on monitoring.
The funds will be used to extend this coverage to new indications. The conditions targeted include depression, type 2 diabetes, chronic inflammatory bowel diseases and chronic liver diseases, with clinical studies already under way or in preparation to validate the impact before commercialisation. Each new indication validated clinically strengthens Sêmeia’s competitive position and broadens its addressable market, making the asset all the more attractive to a potential industrial acquirer.
A regulatory framework that structures the market and secures revenues
Sêmeia’s investment case also rests on a major regulatory catalyst. Remote medical monitoring saw a significant regulatory acceleration in France with the creation of a reimbursement scheme by the national health insurance in 2023, opening up a structured market with recurring revenues for established players. This reimbursement structurally transforms commercial dynamics: it reduces friction in adoption, secures cash flows and creates revenue visibility that investors factor directly into their models.
Sêmeia is part of a broader dynamic. With more selective investments, French medtechs able to address a clearly identified medical need continue to attract investor attention. Technological differentiation, clinical robustness and the ability to scale are now decisive criteria. This is confirmed by the recent 10 million euro fundraising by NeuroClues, which illustrates investors’ enduring appetite for players that can combine clinical robustness and scalability.
At European level, the remote patient monitoring and remote care market is expected to reach 6.26 billion dollars by 2030, with a compound annual growth rate of 14.2%. Remote patient monitoring alone is expected to grow at a compound annual growth rate of 31.4% between 2025 and 2030, driven by advances in wearable biosensors and the integration of predictive analytics into monitoring platforms. In this context, the window to establish oneself as the leading national player before the arrival of major European and American competitors is short. That is precisely what this fundraising is designed to finance.
Our experts by your side
Auris Finance supports company executives in their mergers, acquisitions and corporate finance transactions.
Are you considering a fundraising round, an industrial partnership or a disposal in the medtech or life sciences sector? Our teams are at your disposal to support you.
